Comparative Clinical Analysis of DPP-4 and SGLT2 Inhibitors: A Real-World Switch Study

Key Points

• This research aims to compare the effects of switching to DPP-4 and SGLT2 inhibitors on metabolic markers in patients.
• Conducted a clinical analysis of real-world data regarding medication switching.
• Evaluated HbA1c levels after transitioning to DPP-4 inhibitors.
• Assessed fasting plasma glucose (FPG) and liver-related metabolic parameters after switching to SGLT2 inhibitors.
• Switching to DPP-4 inhibitors led to a significant reduction in HbA1c levels.
• Transitioning to SGLT2 inhibitors improved fasting plasma glucose and liver-related metabolic parameters.